The global digital dose inhaler market size is anticipated to reach USD 5.2 Billion by 2028, expanding at a CAGR of 12.7% during the forecast period, 2021–2028. The growth of the market is attributed to the increasing technological advancements and extensive use of smart computing devices.
Request Free Sample Report Here
Digital dose inhalers are devices that help to provide a particular quantity of medication to the lungs and the drug gets self-administered by patients through inhalation. These devices consist of a pressurized canister that helps to release medication into the human body. Digital dose inhaler also helps patients to track the number of doses consumed as well as control the quantity of the doses digitally due to the built-in sensors.
Allergy spray, digihalers, pump or puffer are some alternative names of digital dose inhaler. These devices are utilized in the treatment and medication delivery of respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. Digital dose Inhalers reduce medication deposition in throat or mouth and also minimizes the requirement for coordination with actuation of the medical device. It provides access to the user as it can connect through Bluetooth to their mobile phone.
Electronic health records (EHRs) and electronic medical records (EMRs) are parts of digital dose inhaler, which are considered advantage to the modern health information technology. Some of the devices possess advanced features that detect inhaler use and also transmit required data.
Market Drivers, Restraints, Trends, and Opportunities
- Growing awareness regarding the benefits of digital dose inhaler market in combination with respiratory medication systems is estimated to boost the market growth.
- Increasing monitoring and management of respiratory diseases are boosting the global digital dose inhalers market growth in coming years.
- Rising predominant factors of respiratory diseases such as COPD and asthma are expected to push the market growth during the forecast period.
- Rising adoption of artificial intelligence (AI) and machine learning (MI) is expected to fuel the market growth.
- High cost of treatments and respiratory inhalers can hinder the market growth.
- Use of digital dose inhaler requires accurate information on various factors, which includes patient compliance and maintenance, and overdose which can restrict the market growth.
Digital Dose Inhaler Market Segment Insights
Dry powder inhaler segment to account a major market share
Based on types the market is bifurcated into metered dose inhaler (MDI) and dry powder inhaler (DPI). The DPI segment is expected to account for a major market share due to rising occurrence of chronic respiratory diseases, such as COPD and asthma. Moreover, growing demand for technological attributes of respiratory devices is driving the segment growth. The existence of propellant components, such as chlorofluorocarbons (CFCs) causes drug irritation problems in MDI. This problem is overcome by usage of the DPI, with less irritant impacts.
Asthma segment is expected to grow at a significant pace
On the basis of applications, the market is segmented into asthma, COPD, and others. The asthma segment is anticipated to expand at a rapid pace during the forecast period owing to rising incidence of respiratory diseases. According to World Health Organization (WHO), around 269 Million people were affected with asthma.
Hospital segment to exhibit a high CAGR
In terms of end-users the market is bifurcated into hospital and clinics. The hospital segment is expected to exhibit a high CAGR during forecast period. Patients prefer to visit hospitals due the presence of medical professionals and technology. However, the clinics segment is estimated to expand at a healthy rate owing to the rising number of clinics catering to breathing related ailments.
North America projected to dominate the market
Based on regions, the market is divided into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market share during forecast period due to increasing geriatric population. Furthermore, the digital dose inhalers market in Asia Pacific is projected to expand at a rapid pace during the forecast period owing to the spread of respiratory diseases, growing urbanization, and increasing pollution and allergens.
Competitive Landscape
Key players competing in the digital dose inhaler market include Glenmark Pharmaceuticals Ltd., AstraZeneca Pl, Novartis International AG, Propeller Health, Philips Respironics, Opko Health, Inc., Teva Pharmaceutical Industries Ltd, Koninklijke Philips N.V., Sensirion AG Switzerland, and H&T Presspart Manufacturing Ltd.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
Global Digital Dose Inhalers Market: IntroductionTransparency Market Research delivers key insights on the global digital dose inhalers market.
In terms of revenue, the global digital dose inhalers market is estimated to expand at a CAGR of ~ 10% during the forecast period, owing to numerous factors, regarding which, TMR offers thorough insights and forecasts in the digital dose inhalers market report.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=18881Digital dose inhalers possess advanced features that aid in the treatment of respiratory diseases such as asthma and COPD (chronic obstructive pulmonary disease).
Dry powder inhalers are drug delivery devices that are used to deliver the dry powder formulation of an active drug for systemic or local effects through a pulmonary route.
It is considered to be a common disease among children.
Surge in the incidences of asthma and increasing combination of genetic predisposition with environmental exposure to inhaled substances and particles can irritate the airways or provoke allergic reactions.
Increase in geriatric population, pollution, allergens, occupational hazards, number of respiratory disease cases, tobacco consumption, and patient population are expected to drive the digital dose inhalers market.
Pune, India – August 28, 2018 —
The Global Asthma Inhaler Device Market has been observing continued growth and is expected to capture a CAGR of 5.2% over the forecast period of 2017–2023, reveals Market Research Future (MRFR), in a minutely analyzed research report.
The high incidence rate of respiratory disorders, particularly COPD and asthma spur the market growth.
LTD. (India), Merck & Co., Inc. (US), Aristopharma Ltd. (Bangladesh), and Intas Pharmaceuticals, Ltd. (India).
Asthma Inhaler Device Market – Updates
May 2018, a new asthma device which requires less force to activate has been created by engineers at the University of Cape Town.
